Condition

Sustained Virologic Response (3)

Anti-Retroviral Agents (1)

Dyslipidemias (1)

Efavirenz (1)

HIV-1-infection (1)

Hepatitis B, Chronic (1)

IL28B Polymorphism (1)

Rilpivirine (1)

Overall Status

Completed (2)

Unknown status (1)

Phase

n/a (1)

phase 4 (1)

Sponsor

Mahidol University (1)

The Catholic University of Korea (1)

The Second Affiliated Hospital of Chongqing Medical University (1)

Intervention

monitoring and regimen change if necessary (1)

only monitoring (1)

peginterferon alfa 2a (pegasys) (1)

peginterferon alfa-2a (pegasys) (1)

regimen change (1)

tenofovir/emtricitabine/efavirenz (1)

tenofovir/emtricitabine/rilpivirine (1)

Study Documents

Intervention Type

drug (3)

other (1)

Funder Type

Other (3)

Study Type

Interventional (2)

Observational (1)

sustained virologic response

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

About Anti-viral Regimen Adjustment on Achieving Complete

Unknown status

Sustained Virologic Response
Hepatitis B, Chronic

only monitoring
+2 more

Chongqing, Chongqing, China

The second affiliated Hospital of Chongqing Medical University

Aug 4, 2021

Anti-Retroviral Agents, Efavirenz, HIV-1-infection Trial (Tenofovir/Emtricitabine/Rilpivirine,

Completed

Anti-Retroviral Agents
+5 more

(no location specified)

May 4, 2019

Sustained Virologic Response, IL28B Polymorphism Trial in Korea, Republic of (peginterferon alfa 2a (pegasys), peginterferon

Completed

Has Results

Sustained Virologic Response
IL28B Polymorphism

peginterferon alfa 2a (pegasys)
peginterferon alfa-2a (pegasys)

Bucheon, Korea, Republic of
+13 more

Feb 3, 2013